MedTrace Logo

Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina

NCT03784391 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2021-04-08

No results posted yet for this study

Summary

The researchers in this trial want to analyze prerecorded patient data which provide information on benefits of the drug nifurtimox in patients with a sudden (acute) and long lasting (chronic) Chagas´ disease an illness caused by parasites mostly transmitted to humans by a bug. They also want to learn how often organs, especially the heart, are affected by the illness in treated and untreated chronic Chaga's patients. In order to find this out medical records of adult and pediatric patients in Argentina will be analyzed.

Conditions

  • Chagas' Disease

Interventions

DRUG

Lampit (Nifurtimox, BAYA2502)

Nifurtimox is a drug already approved in some South American countries since more than 45 years

Sponsors & Collaborators

Eligibility

Min Age
0 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-14
Primary Completion
2020-04-06
Completion
2020-04-06

Countries

  • Argentina

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03784391 on ClinicalTrials.gov